Date: 2015-07-22
Type of information: Financing round
Company: Cevec Pharmaceuticals (Germany)
Investors: Investtodate GmbH (Germany) Frank Ubags, CEO, and Nicole Faust, CSO of CEVEC (Germany) Peppermint VenturePartners GmbH (Germany) Creathor Venture Management GmbH (Germany) NRW.Bank (Germany) KfW Bank (Germany) G.A.T. Holding (Germany) private individuals.
Amount: € 4.5 million
Funding type: financing round
Planned used: Cevec Pharmaceuticals is a producer of tailor-made recombinant glycoproteins and gene therapy vectors. The company focuses on the fully scalable production of tailor-made glyco-optimized proteins and gene therapy vectors. CEVEC will use the new capital to drive further development of its unique CAP®Go and CAP®GT platforms, thus creating new industry standards for the manufacturing of recombinant glycoproteins as well as viral vectors for gene therapy applications. Cevec’s CAP®Go system comprises a comprehensive panel of glyco-optimized human suspension cell lines that differ in their glycosylation capabilities and allow for the recombinant production of a variety of complexly glycosylated proteins such as cytokines, ion channels, virus envelope proteins, coagulation factors or other plasma proteins to name just a few. Most recently, the company published data on glyco-optimized recombinant human alkaline phosphatase and C1 esterase inhibitor, which both showed excellent pharmacokinetic properties in preclinical studies compared to existing recombinant or serum-derived molecules including significantly prolonged serum-half-lives. With its CAP®GT cell lines, CEVEC provides a novel platform for the industrial production of viral vectors for gene therapy applications. CAP®GT cells show a broad viral spectrum supporting lentiviral, adenoviral and adeno-associated viral vectors.
Others: * On July 22, 2015, Cevec Pharmaceuticals announced the successful completion of a financing round of € 4.5 million. New investors included Investtodate GmbH, Frank Ubags, CEO, and Nicole Faust, CSO of CEVEC. Existing investors also participated in this financing. These included Peppermint VenturePartners GmbH, Creathor Venture Management GmbH, NRW.Bank, KfW Bank, G.A.T. Holding as well as a number of private individuals. In this financing round CEVEC was advised by Bergmann zur Hausen & Cie. GmbH.
Therapeutic area: Technology - Services
